Clinical efficacy of surgically assisted transjugular intrahepatic portosystemic shunt for cavernous transformation of portal vein

Table 2 Comparison of basic indicators between the surgically assisted transjugular intrahepatic portosystemic shunt group and control group

Variable	SATIPS group	Control group	P value
Sex			0.104
Man	30	22
Woman	24	31
Age (years)	52.1 ± 14.8	50.4 ± 15.8	0.962
Etiology			0.782
Hepatitis B cirrhosis	25	26
Hepatitis C cirrhosis	5	6
Alcoholic cirrhosis	10	7
Autoimmune cirrhosis	5	3
Cholestatic cirrhosis	4	2
Infection of the umbilical cord at birth	5	8
Weight (kg)	64.9 ± 8.6	70.6 ± 8.9	0.927
Whether to cut the spleen			0.368
Yes	13	15
No	41	37
Height (cm)	166.7 ± 6.6	169.5 ± 6.9	0.974
Laboratory inspection
ALT (U/L)	21.1 ± 14.1	25.7 ± 12.5	0.972
AST (U/L)	27.8 ± 18.4	30.9 ± 14.6	0.776
PTA (%)	64.4 ± 15.5	71.2 ± 14.3	0.566
INR	1.4 ± 0.5	1.3 ± 0.2	0.122
Bilirubin (μmol/L)	31.3 ± 21.7	22.9 ± 14.6	0.118
Albumin (g/L)	33.2 ± 5.1	35.6 ± 5.2	0.465

SATIPS: Surgically assisted transjugular intrahepatic portosystemic shunt; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PTA: Prothrombin time activity; INR: International normalized ratio.